- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05887817
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) (FIVE-STAR)
February 6, 2024 updated by: Koichi Node, Saga University
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in Type 2 Diabetes and Chronic Kidney Disease (FIVE-STAR)
To evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Finerenone is a novel non-steroidal selective mineralocorticoid receptor antagonist (MRA), characterized by a higher selectivity and affinity for mineralocorticoid receptors than conventional steroidal MRA.
In the international phase III trials (FIDELIO-DKD and FIGARO-DKD), finerenone reduced the risk of progression of nephropathy and cardiovascular events in chronic kidney disease (CKD) patients with type 2 diabetes (T2D) who had been on standard treatment for CKD and T2D.
However, the possible mechanistic insights into clinical benefits of finerenone in that patient population are currently very limited.
To address them, in this investigator-initiated, multicenter, placebo-controlled, randomized trial (FIVE-STAR), the investigators seek to assess the effects of finerenone on vascular stiffness and cardiorenal biomarkers in patients with T2D and CKD.
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Koichi Node, MD, PhD
- Phone Number: +81-952-34-2364
- Email: node@cc.saga-u.ac.jp
Study Locations
-
-
-
Saga, Japan, 849-8501
- Saga University Hospital
-
Contact:
- Atsushi Tanaka, MD, PhD
- Phone Number: +81-952-34-2364
- Email: tanakaa2@cc.saga-u.ac.jp
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients who have given their written consent to participate in this study
- Patients who are 20 years of age or older at the time of consent (regardless of gender)
- Patients with type 2 diabetes mellitus
- Patients with chronic kidney disease who meet both of the following criteria; i) eGFR greater than 25 mL/min/1.73 m2 and less than 90 mL/min/1.73 m2, ii) UACR greater than 30 mg/g.cr. and less than 3500 mg/g.cr.
- Patients who have not changed their medications for type 2 diabetes and chronic kidney disease in the past 4 weeks prior to obtaining consent
Exclusion Criteria:
- Patients who are currently taking or have taken MRAs containing finerenone in the past 4 weeks prior to obtaining consent.
- Patients with a history of hypersensitivity to finerenone
- Patients with HbA1c greater than 10%.
- Patients with a serum potassium level of 4.9 mEq/L or higher
- Patients with NYHA class II-IV HFrEF (LVEF <35%)
- Patients with poorly controlled hypertension (e.g., systolic BP >170 mmHg, diastolic BP >110 mmHg, or hypertensive emergencies)
- Patients with a history of ischemic stroke, acute coronary syndrome, cardiovascular surgery or percutaneous intervention, or hospitalization for worsening heart or renal failure in the past 8 weeks prior to obtaining consent
- Patients with a preplanned surgical or percutaneous intervention for coronary artery reconstruction or other cardiovascular disease during the individual observation period.
- Patients with a preplanned treatment such as electrical cardioversion, cardiac resynchronization therapy or pacemaker implantation during the individual observation period.
- Patients with preplanned dialysis or kidney transplantation during the individual observation period.
- Patients with severe hepatic dysfunction (Child-Pugh Class C)
- Patients receiving itraconazole, ritonavir-containing products, atazanavir, darunavir, fosamprenavir, cobicistat-containing products, or clarithromycin, or ensitrelvir
- Patients with Addison's disease
- Patients with active infectious diseases
- Pregnant, possibly pregnant, or lactating patients
- Other patients deemed inappropriate for this study by the principal investigator or subinvestigators (e.g., patients with renal artery stenosis, one kidney, or active malignancy).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo tablets
|
Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning).
For study participants with baseline eGFR less than 60mL/min/1.73
m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert.
The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert.
Study participants with a baseline eGFR of 60 mL/min/1.73m2
or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
|
Experimental: Finerenone
Kerendia® tablets
|
Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning).
For study participants with baseline eGFR less than 60mL/min/1.73
m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert.
The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert.
Study participants with a baseline eGFR of 60 mL/min/1.73m2
or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in CAVI
Time Frame: 24 weeks
|
Change in CAVI at 24 weeks after initiation of protocol treatment compared to baseline
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in UACR
Time Frame: 12 weeks, 24 weeks
|
Proportional changes in geometric mean of UACR at 12 and 24 weeks post-protocol treatment compared to baseline (key secondary endpoint)
|
12 weeks, 24 weeks
|
Change in pentosidine
Time Frame: 24 weeks
|
Proportional changes in geometric mean of pentosidine at 24 weeks post-protocol treatment compared to baseline
|
24 weeks
|
Change in urinary type IV collagen
Time Frame: 24 weeks
|
Proportional changes in geometric mean of urinary type IV collagen at 24 weeks post-protocol treatment compared to baseline
|
24 weeks
|
Change in urinary alpha1-MG
Time Frame: 24 weeks
|
Proportional changes in geometric mean of urinary alpha1-MG at 24 weeks post-protocol treatment compared to baseline
|
24 weeks
|
Change in urinary beta2-MG
Time Frame: 24 weeks
|
Proportional changes in geometric mean of urinary beta2-MG at 24 weeks post-protocol treatment compared to baseline
|
24 weeks
|
Change in urinary NGAL
Time Frame: 24 weeks
|
Proportional changes in geometric mean of urinary NGAL at 24 weeks post-protocol treatment compared to baseline
|
24 weeks
|
Change in urinary NAG
Time Frame: 24 weeks
|
Proportional changes in geometric mean of urinary NAG at 24 weeks post-protocol treatment compared to baseline
|
24 weeks
|
Change in urinary L-FABP
Time Frame: 24 weeks
|
Proportional changes in geometric mean of urinary L-FABP at 24 weeks post-protocol treatment compared to baseline
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Koichi Node, MD, PhD, Saga University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 7, 2023
Primary Completion (Estimated)
February 28, 2025
Study Completion (Estimated)
July 31, 2026
Study Registration Dates
First Submitted
May 24, 2023
First Submitted That Met QC Criteria
May 24, 2023
First Posted (Actual)
June 5, 2023
Study Record Updates
Last Update Posted (Estimated)
February 7, 2024
Last Update Submitted That Met QC Criteria
February 6, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Urologic Diseases
- Endocrine System Diseases
- Disease Attributes
- Diabetes Mellitus
- Renal Insufficiency
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Diabetes Mellitus, Type 2
- Kidney Diseases
- Renal Insufficiency, Chronic
Other Study ID Numbers
- 00002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Diseases
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
Clinical Trials on Finerenone
-
Colorado Prevention CenterBayer; Saint Luke's Hospital of Kansas CityRecruitingHeart Failure | Acute Heart FailureUnited States
-
BayerActive, not recruitingType 2 Diabetes Mellitus | Chronic Kidney DiseaseUnited States
-
BayerActive, not recruitingNon-diabetic Chronic Kidney DiseaseHong Kong, United States, Spain, China, Belgium, Taiwan, Australia, Korea, Republic of, Russian Federation, United Kingdom, Singapore, Malaysia, Japan, Greece, Israel, Hungary, Italy, Czechia, Denmark, Argentina, Bulgaria, Mexico, I... and more
-
BayerCompletedChronic Kidney Disease | Worsening Chronic Heart FailureGermany
-
BayerCompletedPharmacokineticsGermany
-
BayerRecruitingType 2 Diabetes Mellitus | Chronic Kidney DiseaseIndia
-
BayerRecruitingType 2 Diabetes Mellitus | Chronic Kidney DiseaseUnited States, Germany, Argentina, Belgium, Brazil, Canada, Chile, Colombia, France, Italy, Korea, Republic of, Luxembourg, Mexico, Netherlands, Russian Federation, Saudi Arabia, Singapore, Slovenia, Spain, Switzerland, Taiwan, Th... and more
-
BayerCompletedChronic Kidney DiseaseBelgium, Finland, France, China, Hong Kong, Switzerland, United States, Turkey, Greece, New Zealand, Poland, South Africa, Spain, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, ... and more
-
BayerCompletedDiabetic RetinopathyUnited Kingdom, Bulgaria
-
BayerCompletedDiabetic Kidney DiseaseBelgium, Finland, France, Spain, China, Hong Kong, Switzerland, United States, Colombia, Turkey, Greece, New Zealand, Poland, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, Sweden, Austr... and more